The "CAR T-Cell Therapy for Multiple Myeloma - Market Insights and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).
The Multiple Myeloma CAR T-Cell Therapy market report provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Multiple Myeloma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Reasons to Buy
Report Highlights
Key Topics Covered:
1. Key Insights
2. Executive Summary
3. CAR T-Cell Therapy Market Overview at a Glance
3.1 Market Share (%) Distribution of CAR T-Cell Therapy for MM in 2030
4. CAR T-Cell Therapy Background and Overview
4.1 Introduction
4.1.1 CARs Generations
4.1.2 Genetic Engineering of T-Cells
4.1.3 How CAR T-Cell Therapy Works
4.2 The promise of CAR T-cell targeting B cell maturation antigen (BCMA) in multiple myeloma
4.3 Current challenges in CAR T
4.3.1 Therapeutic side effects
4.3.2 CAR T-cells lack of success
4.4 CAR T-cell therapy: Route to reimbursement
4.5 Unmet needs
5. CAR T-Cell Therapy for Multiple Myeloma (MM): 6 Major Market Analysis
5.1 Key Findings
5.2 Market Size of CAR T-Cell Therapy in 6MM
5.2.1 Market Size of CAR T-Cell Therapy by Therapies
6. Market Outlook
7. Emerging Drug Profiles for Multiple Myeloma
7.1 bb2121: Celgene Corporation
7.1.1 Product Description
7.1.2 Research and Development
7.1.3 Product Development Activities
7.2 JNJ-68284528 (LCAR-B38M): Janssen Research & Development
7.2.1 Product Description
7.2.2 Research and Development
7.2.3 Product Development Activities
7.3 P-BCMA-101: Poseida Therapeutics
7.3.1 Product Description:
7.3.2 Research and Development
7.3.3 Product Development Activities
7.4 CAR-CD44v6: MolMed S.p.A.
7.4.1 Product Description
7.4.2 Research and Development
7.4.3 Product Development Activities
7.5 JCARH125 (Orvacabtagene autoleucel): Celgene Corporation
7.5.1 Product Description
7.5.2 Research and Development
7.5.3 Product Development Activities
7.6 Descartes-08: Cartesian Therapeutics
7.6.1 Product Description
7.6.2 Research and Development
7.7 CT053 : CARsgen Therapeutics)
7.7.1 Product Description
7.7.2 Research and Development
7.7.3 Product Development Activities
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/auj3ij
View source version on businesswire.com: https://www.businesswire.com/news/home/20200409005373/en/
Contacts
ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900
Read the original post: